Drug intelligence / Profile preview

BVRS-GamVac

Development stage: Phase 2
Lead developer: Gamaleya Center
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**BVRS-GamVac** is an investigational adenoviral-vector vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology for prevention of Middle East respiratory syndrome caused by Middle East respiratory syndrome coronavirus. It was evaluated as a lyophilized preparation reconstituted for intramuscular administration in a randomized, double-blind, placebo-controlled Phase 1/2 study in healthy adults. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04130594))

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on BVRS-GamVac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BVRS-GamVac.

Explore the full profile